Skip to content

Bioequivalence study of Gliclazide 80 mg mg

Bioequivalence study of Gliclazide 80 mg Tablet (Tehran Chemie) versus Diamicron (SERVIER) Tablet after single oral dosing in healthy volunteers

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220111053692N16
Enrollment
24
Registered
2024-02-29
Start date
2024-03-05
Completion date
Unknown
Last updated
2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bioequivalence study of Gliclazide 80 mg Tablet (Tehran Chemie) versus Diamicron (SERVIER) Tablet after single oral dosing in healthy volunteers.

Interventions

Intervention 1: Intervention group: Receives one tablet of test drug (Gliclazide 80 mg tablet pharmaceutical company Tehran Chemie). Blood samples were taken from the volunteers for 48 hours at the me

Sponsors

Tehran Chemie Pharmaceutical Company
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 18 to 55 years old. Weight in range of 10 % proper body weight. All volunteers should be in a good health condition on the basis of medical history, physical examination, routine blood test. Possessing negative test for hepatitis B surface antigen (HBs-Ag), Antihepatitis-C antibody (anti-HCV) and anti-HIV. just the man

Exclusion criteria

Exclusion criteria: Volunteers with hypersensitivity to Gliclazide were excluded. Those with known history of drug abuse. alcohol consumer or cigarette smokers. Taking medications that have drug interactions with Gliclazide until one month before studying. Disinclination to take the test. Blood donation or blood loss of more than 200 ml in the past month.

Design outcomes

Primary

MeasureTime frame
Drug concentration in plasma samples. Timepoint: In times 0 ? 1? 2? 2/5 ? 3? 3/5? 4? 4/5 ? 5? 5/5 ? 6? 6/5? 7? 7/5? 8? 9? 10? 18? 24? 30? 36 ? 48 Hours after the start of the intervention. Method of measurement: Chromatography.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBardia Jamali

Tam Pouya Consulting & Research Company

info@tampouya.com+98 21 8897 4707

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026